PEMBROLIZUMAB

PEMBROLIZUMAB (12615Y)

pembrolizumab 100 mg/4 mL injection, 4 mL vial
12615Y
Body System:
Manner of administration:Injection
Public
Chemotherapy Items for Public Hospital use
Authority Required

Restriction

Indication: Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer
Treatment phase: Initial treatment

Restriction

Indication: Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer
Treatment phase: Continuing treatment
Quantities & Cost
Max amount # of repeats DPMA Max safety net General Patient Charge
Max amount: 400 mg # of repeats: 6 DPMA: $14,621.47 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Keytruda
(pembrolizumab 100 mg/4 mL injection, 4 mL vial)